Patent law protects pharmaceutical innovation by granting 20-year exclusivity, enabling companies to recoup billions in R&D costs. The Hatch-Waxman Act balances this with a legal pathway for generics, saving U.S. healthcare $373 billion annually while driving down drug prices by up to 90%.
Patent Term Restoration (PTE) helps drug developers recover lost patent time due to FDA approval delays. Learn how the Hatch-Waxman Act works, eligibility rules, current trends, and common pitfalls. With over 1,200 extensions granted between 2010-2020, PTE is crucial for pharmaceutical innovation.